Zai Lab

Zai Lab

Yahoo Finance • 7 days ago

Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading

Asian equities traded in the US as American depositary receipts were marginally lower Tuesday mornin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 26 days ago

OpenAI and Anthropic are making 10 times more revenue than all Chinese AI models combined, research group Rhodium says

BEIJING — China's artificial intelligence models may be enjoying rapid adoption but that isn't yet translating into revenue, raising questions about company valuations. All of China's AI models combined generate only about 10% of the reve... Full story

Yahoo Finance • last month

Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading

Asian equities traded in the US as American depositary receipts started the week lower Monday mornin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up 2% for Week

Asian equities traded in the US as American depositary receipts were rising sharply Friday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 2 months ago

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

BEIJING — Chinese artificial intelligence company Z.ai released a new model Wednesday that the company claims uses entirely homegrown semiconductors to operate. Called GLM-5.3-Flash, the low-cost version of Z.ai's flagship model ranks 10t... Full story

Yahoo Finance • 2 months ago

Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading

Asian equities traded in the US as American depositary receipts were marginally higher Thursday morning, edging up 0.03% to 3,022.75 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by education company Four Seasons Educa... Full story

Yahoo Finance • 2 months ago

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need - U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary NECs from the European... Full story

Yahoo Finance • 3 months ago

Asian Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading

Asian equities traded in the US as American depositary receipts were tracking lower Wednesday mornin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Zai Lab Limited (NASDAQ:ZLAB) is one of the most promising stocks on our list. TheFly reported on June 16 that ZLAB announced that the E... Full story

Yahoo Finance • 5 months ago

Zai Lab announces departure of President and COO Josh Smiley

Biotech firm Zai Lab (ZLAB [https://seekingalpha.com/symbol/ZLAB]) announced that President and COO Josh Smiley is leaving the company [https://seekingalpha.com/pr/20525617-zai-lab-announces-changes-to-senior-leadership-team] immediately a... Full story

Yahoo Finance • 5 months ago

Zai Lab wins FDA fast track status for cancer drug zocilurtatug pelitecan

Zai Lab (ZLAB [https://seekingalpha.com/symbol/ZLAB]) said the U.S. FDA granted fast track designation to its experimental cancer drug zocilurtatug pelitecan for treating extrapulmonary neuroendocrine carcinomas after standard first-line t... Full story

Yahoo Finance • 5 months ago

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has potential to be a fi... Full story

Yahoo Finance • 5 months ago

Zai Lab expects Zoci Phase III enrollment completion in first half of 2027, while targeting first FDA BLA in late 2027

Earnings Call Insights: Zai Lab (ZLAB) Q1 2026 MANAGEMENT VIEW * CEO Ying Du framed the quarter as an inflection in global development, saying, "Zai Lab is at a pivotal moment," and linked the strategy to global execution and productiv... Full story

Yahoo Finance • 5 months ago

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for VYVGART – Zocilurtatug pel... Full story

Yahoo Finance • 6 months ago

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will test the combinatio... Full story

Yahoo Finance • 6 months ago

JPMorgan Cuts PT on Zai Lab Limited (ZLAB) to $32 From $39 – Here’s Why

Zai Lab Limited (NASDAQ:ZLAB) is one of the best high growth healthcare stocks to buy now. JPMorgan cut the price target on Zai Lab Limited (NASDAQ:ZLAB) to $32 from $39 on March 18, reiterating an Overweight rating on the shares. The rati... Full story

Yahoo Finance • 7 months ago

Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies are expanding treatment options and boosting... Full story

Yahoo Finance • 7 months ago

Is Zai Lab (ZLAB) Now A Bargain After Recent 15.8% Share Price Jump?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether Zai Lab's current share price reflects its true worth, you are not alone. Many investors... Full story

Yahoo Finance • 8 months ago

Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028

Earnings Call Insights: Zai Lab (ZLAB) Q4 2025 MANAGEMENT VIEW * Ying Du, Founder, Chairperson & CEO, highlighted that Zai Lab is at a pivotal moment, stating the company is "building a company increasingly defined by global innovation... Full story

Yahoo Finance • 8 months ago

Zai Lab GAAP EPS of -$0.05 beats by $0.30, revenue of $127.6M beats by $4.93M

* Zai Lab press release [https://seekingalpha.com/pr/20414959-zai-lab-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate] (ZLAB [https://seekingalpha.com/symbol/ZLAB]): Q4 GAAP EPS of -$0.05 beats by $0.30... Full story